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MechanismAbstract Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary,
lifestyle, and environmental factors, which favors a chronic positive energy balance, and leads to
increased body fat mass. The incidence of obesity is rising at an alarming rate and is becoming a
major public health concern with incalculable social costs. Indeed, obesity facilitates the develop-
ment of metabolic disorders such as diabetes, hypertension, and cardiovascular diseases in addition
to chronic diseases such as stroke, osteoarthritis, sleep apnea, some cancers, and inﬂammation-
based pathologies. Recent researches demonstrated the potential of natural products to counteract
obesity. Multiple-natural product combinations may result in a synergistic activity that increases
their bioavailability and action on multiple molecular targets, offering advantages over chemical
treatments. In this review, we discuss the anti-obesity potential of natural products and analyze
their mechanisms.
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In 1997, the World Health Organization (WHO) described
obesity as an epidemic hazard worldwide, based on the data
analysis of body mass index (BMI).1 Since then, obesity
incidence increased at an alarming rate and is becoming a
major public health concern.2 Indeed, obesity facilitates the
development of metabolic disorders (e.g. diabetes, hyperten-
sion), and cardiovascular diseases in addition to chronic dis-
eases (e.g. stroke, osteoarthritis, sleep apnea, cancers, and
inﬂammation-based pathologies).3,4 According to studies in
different countries, an obese person incurs health care expendi-
tures at least 25% higher than a healthy person.5 Adding
production losses to health care costs, obesity accounts for a
considerable percentage loss of gross domestic product in most
countries (>1% in US, >3.6% in China).6
Obesity could be iatrogenic, i.e. secondary to drug
treatments (antipsychotic, antidepressant, antiepileptic,
steroids, and insulin), or due to certain diseases (Cushing syn-
drome, hypothyroidism, and hypothalamic defects).7 Obesity
as a primary disorder follows a positive energy balance.
The identiﬁcation of the primary causes of this imbalanceremains challenging and comprises the majority of cases
usually diagnosed after causes for secondary obesity are ruled
out.8 This chronic disease results from complex interactions of
genetic, behavioral, and environmental factors correlating with
economic and social status and lifestyles.9 In fact, obesity is
more frequent in populations living in environments character-
ized by a long-term energy positive imbalance due to sedentary
lifestyle, low resting metabolic rate, or both.10 Causes of obes-
ity involve genes, metabolism, diet, physical activity, and the
socio-cultural environment that characterizes 21st century
living style.11 The identiﬁcation of potential molecular targets
susceptible to be manipulated from external factors, particu-
larly food and drug agents may assist people in gaining control
over appetite allowing obesity prevention. Nutritional genom-
ics could determine which speciﬁc nutrients bring phenotypic
changes that inﬂuence the obesity risk and could establish
which interactions are the most important.12
Global strategies are focused on dietary and lifestyle
modiﬁcations, i.e. restrict calorie intake and increase physical
activity to slow obesity development.13 Researches demon-
strated the potential of natural products to counteract obes-
ity.14 Multiple natural product combinations may result in a
Table 1 BMI values according to the WHO data.
Classiﬁcation BMI*
Under weight <18.5
Normal weight 18.5–24.9
Over weight 25–29.9
Class I obesity 30–34.9
Class II obesity 35–39.9
Class III obesity 40 P
* BMI ofP40–44.9 or 49.9, is morbid obesity. BMI ofP45 or 50,
is super obese.
Natural anti-obesity agents 271synergistic activity that increases their bioavailability and
action on multiple molecular targets, offering advantages over
chemical treatments.15,16 The anti-obesity effects of these com-
pounds are mediated by regulation of various pathways,
including lipid absorption, energy intake and expenditure,
increasing lipolysis, and decreasing lipogenesis, differentiation
and proliferation of preadipocytes.15
2. Deﬁnition
The word obesity comes from the Latin obesitas, which means
stout, fat, or plump. Medically, obesity is a condition in which
excess body fat has accumulated to the extent that it may have
an adverse effect on health, leading to reduced life expectancy
and/or increased health problems.17
3. How to assess obesity?
Body weight is not a good indicator as it does not distinguish
between fat and muscle mass. Various measures, including
body mass index (BMI) and Waist to Hip Ratio (WHR) have
been developed to identify those at risk of serious health
problems.
3.1. Body mass index (BMI)18
Body mass index is a measurement which correlates weight
and height: BMI =Mass (kg)/[Height (m)]2. Table 1 lists the
BMI values according to the WHO data which have been pub-
lished in 2000.
3.2. Waist Circumference (WC) and Waist to Hip Ratio
(WHR)19
WHR is used as a measurement of obesity, which in turn is a
possible indicator of other more serious health conditions,
WHO states that abdominal obesity is deﬁned as a waist–hip
ratio above 0.90 for males and above 0.85 for females. Women
with waist–hip ratios of more than 0.8, and men with more
than 1.0, are at increased health risk because of their fat distri-
bution. WHR has been shown to be a better predictor of car-
diovascular disease than Waist Circumference and body-mass
index.19
WHR is more recent evidence, which deals with the central
distribution of body fat as an indicator of health risks. Waist
distribution of fat has been assessed by calculating the waist/
hip ratio.
WHR ¼Waist Circumference=Hip circumference4. Causes of obesity
At individual level, the combination of excessive food energy
intake and lack of physical activity is thought to explain most
of obesity causes.20 In limited cases, obesity is due to genetic
factors, medical reasons, or psychiatric illness.21 On the other
hand, increasing rates of obesity at a societal level are felt to be
due to easily accessible and palatable diet, increased reliance
on cars, and mechanized manufacturing.22 A 2006 review iden-
tiﬁed ten other possible contributors to the recent increase of
obesity including insufﬁcient sleep, endocrine disruptors,decreased variability in ambient temperature, decreased rates
of smoking, as smoking suppresses appetite, increased use of
medications that can cause weight gain (e.g., atypical antipsy-
chotics), proportional increases in ethnic and age groups that
tend to be heavier, pregnancy at a later age (which may cause
susceptibility to obesity in children), epigenetic risk factors
passed on generationally, natural selection for higher BMI,
and assortative mating leading to increased concentration of
obesity risk factors.23
4.1. Diet
Obesity rates in the US (1971–2000) increased from 14.5% to
30.9%.24 During the same period, there was an increase in the
average amount of food consumed (average increase for
women 335 and 168 cal./day). Most of this extra food energy
was due to the increase in carbohydrates rather than fat
consumption.24
4.2. Sedentary lifestyle
There is a large shift toward less physically demanding work
worldwide. Currently, at least 60% of the world’s population
gets insufﬁcient exercise, due to increased use of mechanized
transportation and a greater prevalence of labor-saving tech-
nology at home.25 The WHO indicates people worldwide are
taking up less active recreational pursuits. In both children
and adults, there is an association between television viewing
time and the risk of obesity.26
4.3. Genetics
Like many other medical conditions, obesity is the result of
interplay between genetic and environmental factors. Polymor-
phisms in various genes controlling appetite and metabolism
predispose to obesity when sufﬁcient food energy is present.
People with two copies of the FTO gene (fat mass and obesity
associated gene) have been found on average to weigh 3–4 kg
more and have a 1.67 fold greater risk of obesity compared to
those without the risk allele.27 Some cases of obesity are related
to single-gene mutations, e.g. melano-cortin-4 receptor (MC4R)
gene28, dopamine receptor D4 (DRD4)29, peroxisome prolifera-
tor-activated receptor y2 (PPARy2)30 or the leptin genes.31
4.4. Medical and psychiatric illness
Certain physical and mental illnesses and medications used
to treat them can increase the risk of obesity. Medical
illnesses that increase obesity risk include several rare genetic
272 G.A. Mohamed et al.syndromes (Cohen syndrome), as well as some congenital or
acquired conditions: hypothyroidism, growth hormone deﬁ-
ciency,32 and eating disorders (binge eating disorder and night
eating syndrome).33 The risk of overweight and obesity is
higher in patients with psychiatric disorders than in persons
without psychiatric disorders.34
4.5. Social determinants
Genetic inﬂuences are important to understand obesity. They
cannot explain the current dramatic increase in obesity.
Though, excess energy consumption than energy expenditure
leads to obesity on individual basis. The cause of the shifts in
these two factors on societal scale is much debated.35 In devel-
oping countries women of a high social class were less likely to
be obese. No signiﬁcant differences were seen among men of
different social classes. In the developing world, population
of high social classes had greater rates of obesity.36 Smoking
has a signiﬁcant effect on an individual’s weight. Those who
quit smoking will gain an average of 4.4 kg (men) and 5.0 kg
(women) over ten years. However, changing rates of smoking
have little effect on the overall rates of obesity.37
4.6. Infectious agents
The study of infectious agent’s effect on metabolism is still in
its early stages. The gut ﬂora in obese and lean individuals can
affect the metabolic potential. This apparent alteration is
believed to confer a greater capacity to gain energy contribut-
ing to obesity. An association between viruses and obesity has
been found in humans and several different animal species.38
4.7. Pathophysiology
Leptin and ghrelin are internal mediators that affect feeding
and appetite. Ghrelin is produced by the stomach modulating
short-term appetitive control (i.e., to eat when the stomach is
empty and to stop when the stomach is stretched). Leptin is
produced by white adipose tissue to signal fat storage reserves
in the body and mediates long-term appetitive controls (i.e., to
eat more when fat storages are low and less when fat storages
are high). It plays a critical role in the regulation of body
weight and energy balance by inhibiting food intake and stim-
ulating energy expenditure.39 Although, administration of lep-
tin may be effective in a small subset of obese individuals who
are leptin deﬁcient. Most obese individuals are thought to be
leptin resistant and have been found to have high levels of lep-
tin.40 This resistance is thought to explain in part why admin-
istration of leptin has not been shown to be effective in
suppressing appetite in most obese people.41 Although leptin
and ghrelin are produced peripherally, they control appetite
through their actions on the central nervous system. Thus, a
deﬁciency in leptin signaling either via leptin deﬁciency or lep-
tin resistance leads to overfeeding and may account for some
genetic and acquired forms of obesity.41,425. Pathologies associated with obesity and its effects on health
In addition to, mechanical effects on the body (i.e., exacerbat-
ing osteoarthritis and back pain due to extra weight) becauseof the extra weight placed on the skeleton, obesity is associated
with a higher incidence of several pathologies.
5.1. Diabetes mellitus
Accumulated data demonstrate the association between obes-
ity and noninsulin-dependent diabetes mellitus, which is the
most common primary form of diabetes and impaired glucose
tolerance. In obese individuals, adipose tissue releases high
amounts of non-esteriﬁed fatty acids, glycerol, pro-inﬂamma-
tory cytokines, and hormones. They are linked with the devel-
opment of insulin resistance, which generate compensatory
hyperinsulinemia with overstimulation of pancreatic cells and
reduction of insulin receptors.43
5.2. Hypertension
Epidemiological studies have demonstrated that 65–75% of
the risk of hypertension is accounted for by obesity.44 Endocri-
nological studies of the adipose tissue revealed links between
obesity and hypertension, likely consequent to the fact that
the adipose tissue secretes bioactive molecules and
immunomodulators.45
5.3. Dislipidemia
Obesity is the most common cause of dislipidemia. Lipid over-
supply in a state of obesity, hyperinsulinemia, and/or insulin
resistance results in increased non-esteriﬁed fatty acid avail-
ability and, in turn, higher TG stores in non-adipose tissues,
e.g. the muscle, liver, and pancreas.46,47 Fatty acid-induced dis-
orders are referred to as lipotoxicity. Thus, elevated TG level is
often accompanied by a slight increase in total cholesterol and
a marked drop in high-density lipoprotein (HDL) cholesterol.
Moreover, low-density lipoproteins (LDL) rich in TG, par-
tially metabolized by hepatic lipase, are converted into small
LDL, with higher atherogenic potential.48
5.4. Cardiac alterations
Obesity increases the risk of heart failure, sudden cardiac
death, angina or chest pain, and abnormal heart rhythm.49
Increased electrical alterations in obesity lead to frequent ven-
tricular dysrhythmias even in the absence of heart dysfunction.
The annual sudden cardiac death rate was nearly 40 times
higher in obese people than in non obese population.50
5.5. The metabolic syndrome
Obesity is the major component of the metabolic syndrome
(multiple metabolic disorders). This syndrome is characterized
by the co-occurrence of multiple metabolic disorders, namely
overall and abdominal obesity, insulin resistance, hyperten-
sion, hyperglycemia, impaired glucose tolerance, and the com-
bination of low HDL cholesterol and elevated TG level.51
5.6. Lung diseases
Obesity is associated with an increased risk of chronic respira-
tory disorders (e.g. asthma, hypoventilation syndrome, and
Natural anti-obesity agents 273sleep apnea). Accordingly, weight loss often leads to symptom-
atic improvement.52
5.7. Cancer
The link between diet, obesity, and cancer is not completely
understood, but the rising world-wide trend in obesity and
cancer might be at least in part causal. The putative cause of
these obesity-related cancers has been primarily ascribed to
excess estrogen production by the adipose tissue, inﬂammation
due to adipocytokines secreted by adipocytes, inﬁltrating mac-
rophages or associated stromal cells that might also play an
important role.53,54
5.8. Neurological disorders
Psychological damage caused by overweight and obesity
ranges from lowered self-esteem to frank clinical depression.
Indeed, rates of anxiety and depression are three to four times
higher among obese individuals.55 Obesity signiﬁcantly
increases the risk of Alzheimer’s disease. A strong correlation
exists between BMI and high levels of amyloid, i.e. the protein
that accumulates in the Alzheimer’s brain, destroying nerve
cells and producing cognitive and behavioral problems.56
5.9. Treatment of obesity
Diet, exercise, pharmacotherapy, behavioral therapy, and life-
style modiﬁcation each can produce a modest weight loss in
the severely obese. Pharmacotherapy, in addition to diet and
exercise, has been demonstrated to facilitate a weight loss of
2–10% per year.57 Long-term maintenance of signiﬁcant
weight loss, continues to be the most challenging problem in
the medically based treatment for obesity.6. Prevention of obesity
As a result of the recent exponential increase in obesity, the
American Heart Association has released several guidelines
for identiﬁcation and early intervention for both adult and
adolescent weight gain.58 Losing weight can reverse the harm-
ful health effects attributed to excess weight, and may improve
or prevent obesity-related diabetes mellitus, dyslipidemia,
hypertension, and diastolic cardiac dysfunction.59
6.1. Dietary intervention
Arrays of diets have been proposed for weight loss in obese
patients. Commercial weight loss programs have become
increasingly popular for targeted weight loss. However,
long-term success is variable, and directly related to patient
compliance with these programs. The proposed weight loss
programs involved an in person center-based program, a tele-
phone-based weight loss counseling program, and a control
group of ‘‘usual care’’. The usual care group received individ-
ualized weight loss counseling sessions and monthly contacts;
however they did not receive free prepackaged meals. The
patients participating in the center and telephone-based groups
were provided with prepackaged food items and a plannedmenu. They were encouraged also to make behavioral changes
regarding physical activity.60
6.2. Diet control
The daily requirements of persons with moderate physical
activity vary with age and sex, (3200–2550 kcal for males
in temperate climate and 2300–1800 kcal for females).
800–1000 kcal/day ranges are frequently used in weight reduc-
tion programs. Fasting or semi-starvation is sometimes
proposed as a mean of weight reduction in obesity.61 Main-
taining a well-balanced diet (rich in ﬁbers and low in fats
and containing multiple vitamins) will provide the body with
nutrients required to function properly.61 Nutrition education
is important for weight management (e.g., low-fat food may
still cause weight gain, since both protein and carbohydrates
can be metabolically converted to fat). Low calorie diets
(<1200 kcal/day) and very low calorie diets (<800 kcal/day)
may be associated with diverse effects such as increased uric
acid level, increased risk of gall stone formation, loss of lean
body mass, electrolyte disturbances and mild liver
dysfunction.62
The number of calories needed to maintain a certain body
weight can be estimated by multiplying a person’s REE times
an appropriate Activity Factor (AF) where REE is the Resting
Energy Expenditure and the AF is the Activity Factor (AF) for
different levels of activity.63
6.3. Physical activity
Weight gain and obesity are responses to long term positive
energy balance where:
Energy Balance ¼ Energy Intake Energy Expenditure
Energy balance involves equilibrium between calorie intake
and energy utilization (physical activity, basal metabolism, and
adaptive thermogenesis).64 The development of overweight
and obesity is a consequence of the easy and cheap availability
of high-calorie foods, which is combined with sedentary life-
style (Fig. 1). A variety of exercises such as walking, cycling,
swimming, and aerobics are effective and easy to implement.
Regular physical activity is an essential component to lose
weight. To lose weight, one must achieve a negative energy bal-
ance (i.e., decreased energy intake and increased energy expen-
diture). Overweight patients who participate in at least 30 min
of moderate physical activity most days of the week, or who
have moderate to high cardio-respiratory ﬁtness have
decreased all-cause mortality than those who are sedentary
and un-ﬁt.65,66 Exercise as a treatment for obesity is most effec-
tive when combined with diet and weight-loss programs. Exer-
cise alone without dietary changes will have a limited effect on
weight because one has to exercise a lot to lose one pound.
However, regular exercise is important to maintain a healthy
weight for the long term. Another advantage of regular exer-
cise as part of a weight-loss program is a greater loss of body
fat versus lean muscle in comparison to diet alone.59
6.4. Pharmacotherapy
Medications can facilitate weight loss in obese persons. Similar
to Weight Loss Surgery, there are certain BMI criteria
Figure 1 Fundamental principles of energy balance.
Table 2 Some common anti-obesity drugs.
Drug Mechanism of action Eﬀect on weight Side eﬀects
Phentermine
(Fastin)
Diethylpropion
Appetite suppressant reduces food intake.
Sympathomimitic amine causes release of
norepinephrine by the cells.
3.6 kg at
6 months
Headache, insomnia, irritability, palpitation and
nervousness
Fluoxetine
(Prozac)
Reduces food intake through selective inhibition of
serotonin re-uptake.
4.74 kg at
6 months and
3.15 kg at 1 year
Agitation and nervousness
Sibutramine
(Meridia)
Reduces food intake through combined
norepinephrine and serotonin re-uptake inhibition.
4.45 kg at 1 year Headache, insomnia, dry mouth and
constipation. Long term treatment increases the
risk of heart attack and stroke.
Orlistat
(Xenical)
Lipase inhibitor reduces fat absorption. 2.59 kg at
6 months and
2.89 kg at 1 year
Diarrhea, ﬂatulence, bloating, abdominal pain,
and dyspepsia
Rimonabant
(Acomplia)
Selective CB1 receptor blocker reduces food intake. 51 kg at 1 year Nausea, dizziness, arthralgia, and diarrhea
274 G.A. Mohamed et al.necessary to prescribe pharmacotherapies. The patient
must have a BMI greater than 30 kg/m2 or BMI of at least
27 kg/m2 with obesity-related co-morbidities. Medications are
often required long-term as many persons regain weight
when they are discontinued. In addition, person’s compliance
to these daily medications is of concern, especially in light of
cost, potential lack of insurance coverage, and possible side
effects. The ﬁrst class of medication used for weight control
causes symptoms that mimic the sympathetic nervous system.
They cause the body to feel ‘‘under stress’’ or ‘‘nervous’’. As a
result, the major side effect of this class of medication is
high blood pressure. These medications also decrease
appetite and create a sensation of fullness. Another class of
anti-obesity medications suppresses appetite by increasing
the level of neurotransmitters at the synapse junction, where
hunger and fullness (satiety) are regulated by brain neurotrans-
mitters (e.g., serotonin, norepinephrine, and dopamine).
Several common medications for weight loss are listed in
Table 2.67–706.5. Diuretics
Diuretics cause loss of ﬂuids that may result in gradual weight
reduction. Diuretics cause temporary weight loss with no loss
in body fat. Their use should be avoided due to the serious side
effect of electrolytes imbalance.71,726.6. Surgical treatment for obesity
Bariatric or Weight Loss Surgery (WLS) was previously cate-
gorized as malabsorptive, restrictive, or a combination of both.
However with a greater understanding of the extensive
neural-hormonal effects of WLS on satiety, hunger and metab-
olism, the above mentioned broad categories are no longer
appropriate. In fact, today Bariatric or WLS is perhaps better
referred to as Metabolic Surgery. The most common metabolic
surgical procedures include Roux-en-Y gastric bypass, adjust-
able gastric band, sleeve gastrectomy, and biliopancreatic
Table 3 Classes of dietary phytochemicals.
Phytochemical Examples Eﬀects
Polyphenols Simple phenolic acids
(e.g. ferulic, caﬀeic)
Ferulic acid has hypolipidemic eﬀect and lowers the risk of high fat diet-induced obesity
and reduces serum cholesterol76
Stilbenes (resveratrol) Resveratrol decreases LDL-cholesterol and prevents lipid oxidation77
Decreases adipogenesis by downregulating adipocyte transcription factors, altering the
expression of adipocyte speciﬁc genes78
In mature adipocytes, it increases lipolysis, induces apoptosis, and reduces lipogenesis,
proliferation and lipid accumulation79
Dietary supplements of resveratrol, vitamin D, quercetin, and genistein reduce weight
gain and body fat leading to potential novel therapies for obesity77,80,81
Curcumins Prevent lipid accumulation82
Regulate energy metabolism and decrease level of intracellular lipids83
In adipose tissues, curcumins suppress angiogenesis necessary for tissue growth84
Curcumins regulate transcription factors that play key roles in adipo- and
lipogenesis83,85
Lignans (e.g.
secoisolariciresinol,
matairesinol)
They are converted to mammalian lignans enterodiol and enterolactone that may reduce
the risk of chronic diseases including obesity86
Flavonoids (e.g. quercetin) Attenuate in vitro adipogenesis by activating AMPK signal pathway in preadipocytes
and decreasing expression of adipogenesis related factors87
Alkaloids Capsaicin Attenuates obesity-induced inﬂammation, obesity related metabolic disorders, and liver
diseases88
Reduces food intake and increases energy expenditure and lipid oxidation89
Ephedrine Increases norepinepherine causing appetite suppression90
Produces thermogenic eﬀect (increase basal metabolic rate) and energy expenditure91
Caﬀeine Stimulates fat breakdown, potentiates the anorectic and thermogenic eﬀects in addition
to its diuretic eﬀect91,92
Nicotine Decreases food intake and increases fat oxidation and energy expenditure93,94
Terpenoids Abscisic acid (ABA) Eﬀective in treatment of diabetes and obesity-related inﬂammation95
Carotenoids Carotenoids may prevent inﬂammation associated diseases such as obesity and
atherosclerosis96
Lycopene Lycopene rich diets lower the risk of CVD (inhibition of LDL oxidation and lipid
peroxidation)97
Organosulfur Ajoene Decreases cholesterol synthesis, lowers blood pressure, and stimulates non-speciﬁc
immunity98
Decreases fat cell number suggesting some therapeutic possibility for obesity99
Phytosterols Diosgenin,
Campesterol, Brassicasterol,
Sitosterol
High intakes of these sterols can protect against atherosclerosis and decrease LDL-
cholesterol100
Phytosterols compete with cholesterol for micelle formation in the intestinal lumen and
inhibit cholesterol absorption101
Protodioscin Signiﬁcantly reduces blood levels of TG, cholesterol, LDL and increases high-density
lipoproteins102
Diosgenin Inhibits accumulation of TG and expression of lipogenic genes103
Natural anti-obesity agents 275diversion.73 The National Institute of Health consensus has
suggested the following guidelines for surgery in obese
patients:
a- Patients with BMI more than 40.
b- Patients with BMI more than 35 who have serious med-
ical problems such as sleep apnea, that would be
improved with weight loss.6.7. Natural products for treatment of obesity
The potential of natural products for treating obesity is under
exploration. This may be an excellent alternative strategy for
developing future effective, safe anti-obesity drugs.74 A variety
of natural products, including crude extracts and isolated pure
natural compounds can induce body weight reduction andprevent diet-induced obesity. Therefore, they have been widely
used in treating obesity.75
6.7.1. Dietary phytochemicals
Dietary phytochemicals might be employed as anti-obesity
agents because they may suppress the growth of the adipose
tissue, inhibit differentiation of preadipocytes, stimulate
lipolysis, and induce apoptosis of existing adipocytes, thereby
reducing adipose tissue mass (Table 3 and Fig. 2).
6.7.2. Natural products
6.7.2.1. Natural products with lipase inhibitory effect. Dietary
fat is absorbed by the intestine when it has been subjected to
the action of pancreatic lipases. Pancreatic lipase is a key
enzyme in dietary triacylglycerol absorption, hydrolyzing
triacylglycerols to monoacylglycerols and fatty acids. Few
Polyphenols
Simple phenolic acids
Stilbenes
Curcuminoids
Chalcones
Lignans
Flavonoids
Isoflavones
Caffeic acid (Fruits, Coffee beans, Soy 
beans)
Ferulic acid (Fruits, Soy beans)
Chlorogenic acid (Fruits, Coffee beans, 
Soy beans)
Resveratrol (Grapes, Red wine)
Curcumin (Tumeric, Curry, Mustard)
Phlorizin (Tea)
Naringenin (Tomatoes)
Matairesinol (whole grains, legumes, fruits)
Secoisolariciresinol (whole grains, legumes, 
fruits)
Flavonol
Flavanols
Anthocyanins
Flavones
Flavanones
Flavanonols
Kaempferol (Fruits, vegetables)
Quercetin (Fruits, vegetables)
Proanthocyanidins (apple, Cocoa, grape 
seeds)
Catechins (Apple, red wine)
Cyanidin (Black berries)
Luteolin (Tea, fruits, vegetables)
Naringenin (Citrus fruit, tomatoes)
Taxifolin (Red onion)
Genistein (Soy beans)
Daidzein (Soy beans)
Terpenoids
Organosulfurs
Phytosterols
Carotenoids
Sesquiterpenes
Lycopene (Tomatoes)
Lutein (Dark green vegetables)
Carotene (Orange- yellow vegetables)
Absisic acid (fruits, vegetables)
Allyl sulfide (Garilic, Onion)
Allicin (Garilic, Onion)
Allixin (Garilic, Onion)
Protodioscin (Caltrop)
Diosgenin (Foenugreek, wild yam)
Guggulterone (Guggul plant)
Alkaloids
Xanthine
Phenylalkylamine Ephedrine (Ephedra sp.)
Synepherine (Citrus aurantium)
Caffeine(Thea sinensis)
Alkylamide Capsaicin (Chilli pepper)
Pyridine Nicotine (Nicotinea tabacum)
Figure 2 Classiﬁcation of common dietary phytochemicals.
276 G.A. Mohamed et al.substances interact directly with the lipases as orlistat. It is a
derivative of the naturally-occurring lipase inhibitor from
Streptomyces toxytricini.104 Orlistat inhibits by forming a
covalent bond to the lipase’s serine active site.105 Although it
is clinically approved for obesity treatment, it has certain
unpleasant gastrointestinal side-effects.106Natural products provide a vast pool of pancreatic lipase
inhibitors.107 A wide variety of plant products such as sapo-
nins, polyphenols, ﬂavonoids, and caffeine possess lipase
inhibitory effects (Table 4).108 Several carbohydrates also pos-
sess pancreatic lipase inhibitory effects,109 for example chitin/
chitosan.110 Many metabolites from microorganisms, includ-
Figure 3 Proposed anti-obesity mechanisms of green tea.
Natural anti-obesity agents 277ing lipstatin from S. toxytricini and panclicins from Streptomy-
ces sp. also possess pancreatic lipase inhibitory activity.111
Different types of tea (e.g., green, oolong, and black tea) are
among the most widely-studied materials for lipase inhibitors.
Various polyphenols (e.g., L-epicatechin, epicatechin gallate
(ECG), epigallocatechin (EGC) and epigallocatechin gallate
(EGCG)) isolated from tea leaves showed strong inhibitory
activity against pancreatic lipase (Fig. 3).112 These polyphenols
acquire galloyl moieties within their chemical structures and/or
polymerization of their ﬂavan-3-ols for enhanced pancreatic
lipase inhibition.113
6.7.2.2. Natural appetite suppressants. Body weight regulation
through appetite control is a multifactorial event resulting
from neurological and hormonal interrelationships. A line
of evidence indicates that serotonin, histamine, dopamine,
and their associated receptor activities are closely associated
with satiety regulation. These receptors may enable better
targets for drugs treating obesity through energy intake
reduction.127 Agents that act via peripheral satiety peptide
systems alter the various hypothalamic neuropeptide levels.
Also, they alter the key CNS appetite monoamine neuro-
transmitter levels and may be suitable candidates for appetite
suppressants.128 Appetite suppressants control hunger centers
in the brain, resulting in a sense of fullness. However, ghrelin
secretion in the stomach may increase with decreased food
intake, stimulating more food intake. Therefore, ghrelin
antagonism may decrease the appetite that potentially occurs
with decreased feeding, thus, may be a potential adjunctive
treatment for obesity. An example of a natural appetite
suppressant is Hoodia gordonii. It regulates appetite and sig-
niﬁcantly reduces calorie intake and boosts weight loss.129
Natural ()-hydroxycitric acid (HCA) from Garcinia cambo-
gia, is a potential natural appetite suppressant. It is available
under the names HCA-SX and Super CitriMax.130 Hyperi-
cum perforatum increases the serotonin quantity present
within synaptosomes by inhibiting synaptosomal uptake of
serotonin, which suppresses the appetite and reduces food
intake. Thus increased serotonergic transmission might be
the link between antidepressant and anti-obesity activities of
H. perforatum.131 Some natural appetite suppressants are
listed in Table 5.Table 4 Natural pancreatic lipase inhibitors.
Source U
Panax japonicus (rhizomes) C
Thea sinensis (oolong tea) C
Cassia mimosoides Pr
Trigonella foenum graecum L. (seed) C
Salix matsudana (leaf) Po
Vitis vinifera C
Salvia oﬃcinalis L. (leaf) M
Cassia nomame F
Coﬀea canephora C
Citrus unshiu H
Chitosan-chitin C
Streptomyces toxytricini (fungus) L
Actinomycetes sp. V
Caulerpa taxifolia (marine algae) C6.7.2.3. Natural energy expenditure stimulants. Excessive adi-
posity results from energy imbalance, where the consequences
of excessive food intake are not balanced by increasing energy
expenditure. Energy expenditure has many components, and
can be classiﬁed into physical activity, obligatory energy
expenditure, and adaptive thermogenesis.140 To regulate body
weight and energy expenditure, mammalian brown adipose tis-
sue (BAT) establishes non-shivering thermogenesis through
dissipation of excess energy as heat. BAT plays an important
role in obesity control by controlling energy balance through
UCP1 (Uncoupling protein). UCP1 is responsible for oxidative
phosphorylation. Thus, searching for substances that up-
regulate UCP1 gene expression may be a worthy strategy for
achieving obesity control through increased energy expendi-
ture.141 For example, the ethanolic extract of Solanum tubero-
sum activated the expression of UCP in BAT and the liver, and
signiﬁcantly reduced fat weight.142 Many natural compounds
have been proposed as treatments for obesity via enhanced
energy expenditure including caffeine, capsaicin, and green
tea and its extract.143
6.7.2.4. Natural adipocyte differentiation inhibitors (decreased
lipogenesis). Adipocytes play a central role in the maintenance
of lipid homeostasis and energy balance by storing triglycer-
ides and releasing free fatty acids in response to change insed part and/or active constituents
hikusetsusaponins114
rude aqueous extract (caﬀeine)115
oanthocyanidin116
rude ethanolic extract117
lyphenol (PP)118
rude ethanolic extract119
ethanolic extract (carnosic acid)120
lavan dimers121
aﬀeine, chlorogenic acid, neochlorogenic, and feruloylquinic acids122
esperidin123
hitosan (80%), chitin (20%)124
ipistatin111
alilactone125
aulerpenyne126
Table 5 Examples of natural appetite suppressants.
Source Used part and/or active constituents
Panax ginseng (root) Crude saponins132
Garcinia cambogia ()-Hydroxycitric acid (HCA)133
Camellia sinensis (leaf) ()-Epigallo-cathechin gallate (EGCG)134
Hoodia gordonii and
H. pilifera
Steroidal glycoside (P57AS3)135
Phaseolus vulgaris and
Robinia pseudoacacia
Lectins136
Pinus koraiensis
(pine nut)
Pine nut fatty acids137
Ephedra species Ephedrine138
Citrus aurantium Synephrine139
Hypericum perforatum Total extract131
Table 6 Natural adipocyte differentiation inhibitors.
Source Used part and/or
active constituents
Garcinia cambogia ()-Hydroxycitric acid (HCA)148
Glycine max (product of GIBCO) Genistein149
Chili pepper (Capsicum) Capsaicin150
Fish oil Docosahexaenoic acid151
Palm oil c-tocotrienol152
Sterol (product of Sigma) b-sitosterol145
Camellia sinensis (green tea) ()-Epigallocatechin gallate153
Panax ginseng Ginsenosides154
Silybum marianum Silibinin155
Garlic Ajoene156
Rosmarinus oﬃcinalis Carnosic acid157
Curcuma longa Curcumin158
Humulus lupulus Xanthohumol159
278 G.A. Mohamed et al.energy demands.144 Natural products that speciﬁcally target
adipogenesis inhibition had been considered promising
potentials in obesity treatment. Fatty acids, particularly
polyunsaturated fatty acids (PUFA) act as signal transducing
molecules in adipocyte differentiation.145 Thus, PUFA play a
central role in suppressing lipogenesis and regulating adipocyte
differentiation through suppression of late-phase adipocyte
differentiation.146 Several natural products have apoptotic
effects on maturing pre-adipocytes (eg. esculetin, resveratrol,
quercetin, genistein, EGCG, capsaicin, and conjugated linoleic
acids).147 Examples of some natural products with adipocyte
differentiation inhibitory effect are given in Table 6.
6.7.2.5. Natural lipid metabolism regulators (increased lipoly-
sis). The pharmacological targeting of lipolysis can be
achieved by stimulating triglyceride hydrolysis in order to
diminish fat stores, thereby combating obesity. The ﬂavonoids
from Nelumbo nucifera leaves are examples of the natural
products involved in b-adrenergic receptor activation.160
Table 7 shows examples of natural products, which promote
lipid metabolism.
6.7.2.6. Natural products with combined effect. As mentioned
above, many natural products show anti-obesity activities with
varying mechanisms. Perhaps the recommended approach to
search for more efﬁcient obesity treatments and achieving
the synergistic effects of natural products should seek treat-
ments using multiple products or products that have multiple
activities.143 Green tea is a good example of a natural drug
which possesses multi-functional anti-obesity activities.
Researches have proved the anti-obesity activity of catechins
which is due to the combined actions of appetite reduction,
greater lipolytic activity and energy expenditure, and less lipo-
genic activity and adipocyte differentiation.112,113
The aqueous extract of Hibiscus sabdariffa (mainly antho-
cyanins) has potential anti-obesity mechanisms including
anti-hyperglycemic, lowering plasma cholesterol level, gastric
and pancreatic lipase inhibition, thermogenesis stimulation,
inhibition of lipid droplet accumulation in fat cells (no effects
on adipose conversion), and fatty acid synthase inhibition.167
G. cambogia extract (HCA) has multi-functional anti-obes-
ity effects. It inhibits adipocyte differentiation, reduces fatty
acid synthesis (lipogenesis) and epididymal fat accumulation
through reducing ATP-citrate lyase activity, and suppresses
appetite.148 Pomegranate extract (ellagic and tannic acids) alsohas dual anti-obesity effects. It inhibits pancreatic lipase activ-
ity and suppresses energy intake. Its effect on energy intake
was similar to sibutramine but with a different mechanism.168
Arachis hypogaea (Peanut) shell extract inhibits fat absorption,
activates lipid metabolism in the liver, and reduces adipocyte
lipolysis.169 Apium graveolens juice signiﬁcantly lowers TG
concentrations and total cholesterol levels in animals fed with
high-fat diet.170 Ginger has a dual antiobesity effect. Gingerol
and shogaol increase the metabolic rate and thus help to ‘‘burn
off’’ excessive fat and also suppress the absorption of
calorie-dense dietary fats from the intestines. The ginger
extract inhibits the absorption of dietary fat by the intestine.171
6.7.2.7. Enzymatic treatment of obesity. Eating a whole fresh
pineapple (Ananas comosus, A. sativus) per day can decrease
the body weight by 100 pounds on a pineapple regimen. Its
content of bromelain enzyme helps to digest both proteins
and fats.167
6.7.2.8. Laxatives
6.7.2.8.1. Bulk producers.Many herbs and natural products are
signiﬁcant in the treatment of obesity through bulk-producing
activity that produce a sense of fullness, thereby reducing
appetite.60 Fibers act through slowing the movement of food
and acidic ﬂuid from the stomach to the intestines. They
may help people with duodenal ulcers by reducing the expo-
sure of the small intestine to stomach acids. Dietary ﬁbers
lower cholesterol, reduce elevated blood levels of triglycerides,
and protect against cancer and digestive disorders.172
National cancer Institute recommends incorporating 30 g
of ﬁbers into the daily diet. The bulk producers include natural
polysaccharides or celluloses, in addition to semisynthetic
polysaccharides (methylcellulose and carboxymethylcellulose)
and synthetic resin polycarbophil.172
The bran layers of grains are the most important source of
ﬁbers. Bran contains more than 40% dietary ﬁbers and is a
convenient source of intestinal bulk. Mucilages in plant seeds
have been shown to decrease glucose and insulin levels during
post-meal and fasting periods in healthy and diabetic persons.
When taken before meal they have also been shown to
decrease weight and hunger in obese persons. It was also
reported that mucilage contents of bran such as oat bran are
effective cholesterol lowering agents. A diet with 5% oat bran
Table 7 Natural lipid metabolism regulators.
Source Used part and/or active constituents
Morus albam, Melissa oﬃcinalis, Artemisia capillaries (leaf) Crude aqueous extract161
Curcuma longa L. Curcumin and curcuminoids162
Glycyrrhiza glabra L. (root) Licorice ﬂavonoid163
Panax ginseng Crude aqueous extract164
Zea mays L. Purple corn color (anthocyanins)165
Soybean Genistein and L-carnitine (soy isoﬂavone)166
Coﬀea canephora Caﬀeine, chlorogenic, neochlorogenic, and feruloyquinic acids108
Natural anti-obesity agents 279showed reduction in total cholesterol and LDL levels of 19%
and 29%, respectively.173
Pectin consists mainly of partially methoxylated galactou-
ronic acids. It is found in a number of fruits and vegetables
(e.g. apples, white inner layer of citrus rind, carrots, cabbage
and okra). It slows down food digestion, helps the body to
get rid of toxic metals, and reduces cholesterol levels by
reducing the plasma LDL fraction.173 Psyllium is a good
source of soluble and insoluble ﬁbers and can be indicated in
the treatment of obesity because it absorbs water in the stom-
ach creating a feeling of fullness and decreases appetite. It is
also beneﬁcial in diabetes and for lowering the cholesterol
level.93,174,175
Other examples of bulk producers are Laminaria spp.
(mucilage algin, polysaccharides laminarin), chitosans, Fucus
vesiculosis (mucilage algin and fucin, cellulose), agar agar from
Gelidium and Petrocladi spp. (polysaccharides agarose and
agaropectin).175
6.7.2.8.2. Stimulant laxative (anthraquinones). Some herbal
preparations used in obesity include anthraquinones contain-
ing plants such as senna (Cassia species), cascara (Rhamnus
species), rhubarb (Rheum palmatum), and aloe (Aloe vera, A.
ferox). The laxative effect of anthraquinones leads to rapid
excretion of foods and water loss which can aid in weight
reduction.175
6.7.2.9. Non calorie sweeteners. Sucrose substituents (e.g. sac-
charin, aspartame, sorbitol) may allow signiﬁcant calorie
reduction in certain patients.176 Glycyrrhizin is a non caloric
triterpene of liquorice root (50–100 times sweeter than
sucrose). Stevioside (Stevia rebaudiana) is 300 times sweeter
than sucrose.176 There are a number of additional low calorie
sweeteners waiting for approval for use in foods and beverages
as neohesperidin dihydrochalcone derived from bioﬂavonoids
of citrus fruits. Currently neohesperidin-DHC synthesized
from Seville oranges has been found to have great potential
in food applications. Naringin isolated from grapefruit (Citrus
paradisi) is converted to naringin dihydrochalcone which is
1000 times sweeter than sucrose and is used to reduce body
weight.177
6.7.2.10. Marine natural products. Iodine is the most important
active component in Fucus vesiculosus, also it contains
polyphenols, polysaccharides, sterols, and other minerals.
Iodine is known to play an important role in the treatment
of obesity. Iodine was believed to stimulate the thyroid gland,
causing weight-loss.178,179
The brown seaweed Undaria pinnatiﬁda contains
fucoxanthin and fucoxanthinol. It was found that fucoxanthinsigniﬁcantly reduced plasma and hepatic triglyceride concen-
trations and the activities of adipocytic fatty acid synthesis,
hepatic fatty acid and triglyceride synthesis, and cholesterol-
regulating enzymes, and signiﬁcantly increased the concentra-
tions of plasma high-density lipoprotein-cholesterol, fecal
triglyceride and cholesterol, as well as fatty acid oxidation
enzyme activity, indicating that fucoxanthin ameliorated the
plasma and hepatic lipid proﬁle, fecal lipids and body fat mass,
hepatic cholesterol metabolism, fatty acid synthesis, and lipid
absorption.180 In addition, fucoxanthin and fucoxanthinol
inhibited both lymphatic triglyceride absorption and the
increase of triglyceride concentration in systemic blood, likely
due to their inhibitory effects on lipase activity in the gastroin-
testinal lumen.181,182
Astaxanthin, a xanthophyll carotenoid, isolated the marine
algae Haematococcus pluvialis, Chlorella zoﬁngiensis, and
Chlorococcum sp. was found to inhibit the increases in body
weight and weight of the adipose tissue, whereas reduce liver
weight, liver triglyceride, plasma triglyceride, and total
cholesterol.183
Krill oil is extracted from Antarctic krill, Euphausia
superba, a zooplankton crustacean rich in phospholipids
carrying long-chain omega-3 PUFAs, mainly EPA and
DHA. Additionally, Krill oil also contains various potent
antioxidants, including vitamins A and E and astaxanthin.184
It has been reported that krill oil could reduce the level of glu-
cose, total cholesterol, triglycerides, LDL and HDL, and could
increase plasma eicosapentaenoic acid (EPA) and docosahexa-
enoic acid (DHA), with no indication of adverse effects on
safety parameters.184,1857. Suggestions and recommendations
a- Be active, walk for 30 min a day especially before break-
fast to burn off fat. Exercise is the best way to get rid of
excess body fat and to maintain good muscle tone.
b- Check with the doctor, underactive thyroid can cause
obesity to be a problem.
c- Rotate foods and eat a variety of foods, ask dietitian to
regulate your food intake and drink 6–8 glasses of liq-
uids every day.
d- Cut down on salt, it makes you thirsty and causes reten-
tion of water.
e- Make sure bowels are regular. Use extra ﬁbers in the diet
every day. Put less food in your plate. Chew slowly.
f- Do not chew gum, because it starts the gastric digestive
juices ﬂowing and will make you feel hungry sooner, in
addition to overworking your digestive system.
280 G.A. Mohamed et al.g- Never consume animal fats; butter, cream, ice cream,
whole milk, rich dressing, mayonnaise, and fried foods.
h- Do not eliminate sources of good fat, containing unsat-
urated fatty acids, such as avocados, olive oil, and nuts.
i- Avoid white ﬂour products, salt, white rice, or processed
foods. Avoid fast food restaurants. Do not consume
sweets such as soda pastries, cakes, doughnuts, and
candy. Eat complex carbohydrates that offer protein:
lentils, plain baked potatoes, sesame seeds, beans, brown
rice, and whole grains.
j- Eat fresh fruits and raw vegetables (good ﬁber sources).
At least one meal a day should be only fruits and
vegetables.
k- Make lunch the main meal of the day, no later than 3
PM to give the body time to burn some calories before
bedtime.
8. Conclusion
Weight management is a life-long process and permanent
weight reduction is difﬁcult to achieve. The ultimate cause of
obesity is an imbalance between calorie intake and energy
expenditure resulting from complex interactions between many
genetic and environmental factors. Obesity is a chronic disease
that affects millions of people worldwide and contributes to
substantial morbidity and mortality. A successful weight
control program must balance calorie intake with energy
expenditure. Diet and exercise have been the mainstays for
weight control. Natural products can play a safe and effective
role with obesity specially those containing ﬁbers, polyphenols,
sterols, and alkaloids. In addition, they are a good supplement
for vitamins and minerals. In general, natural products with
potential action in treatment of obesity act as a general body
cleanser, regulate metabolism, dissolve fat in the body, help
to eliminate craving of food, stimulate glandular secretions,
reduce water retention, boot energy and help in constipation.
However, their use should be in conjunction with regular
exercise, as well as dietary and behavioral modiﬁcations. The
use of multiple phytochemicals might result in synergistic
and enhanced effects.
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